Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 139 participants.

Also called NCT01850901

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 139 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01850901
Other papers using this trial's data
  • Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial Hypertension (Dallas, Tex. : 1979), 2017-04 DOI, PubMed 28264922

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01850901. Randomized; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2016-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension
Acronym
SYMPATHY
Condition
Hypertension
Intervention (Procedure)
Renal sympathetic denervation
Lead sponsor
UMC Utrecht (class: other)
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct01850901
Content hash
f7ce3d49f5b6a86c760bf1b9b7e3de12394e3134cb09f83d9afa551de2df9568